ArticleReviews in cardiovascular medicine2026
Increased Vascular Endothelial Growth Factor Receptor 2 Levels Are Associated With a Higher Occurrence of Coronary Artery Disease in Patients With Obstructive Sleep Apnea.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) has become a vital risk factor for coronary artery disease (CAD). Vascular endothelial growth factor receptor 2 (VEGFR2) participates in the mediation of atherosclerosis, the main underlying pathophysiological basis of CAD, by promoting angiogenesis and inflammation. Chronic intermittent hypoxia, a characteristic of OSA, can induce VEGFR2 expression. Therefore, this study aimed to examine the association between circulating VEGFR2 levels and CAD in OSA patients, an association that has not been well explored in previous research. Methods: This cross-sectional study involved 453 Chinese adults: 345 with OSA and CAD and 108 with OSA alone. The Gensini and SYNTAX scores were used to evaluate the severity of CAD. An enzyme-linked immunosorbent assay (ELISA) was used to measure circulating VEGFR2 levels. Multivariate logistic regression analyses were used to explore the association between the circulating VEGFR2 levels and CAD and also to determine the independent associations. Multivariate linear regression analysis was used to determine the relationship between VEGFR2 levels and the severity of CAD. Results: Patients with OSA and CAD demonstrated remarkably higher circulating VEGFR2 levels compared with those patients with OSA alone (median interquartile range (IQR): CAD 10.9 (8.26-14.6) vs. non-CAD 8.25 (5.87-10.3) ng/mL; * Conclusions: In Chinese patients with OSA, those with CAD exhibited higher circulating VEGFR2 levels than those without CAD. Increased VEGFR2 levels were independently associated with the presence and severity of CAD, suggesting a potential role of VEGFR2 as a biomarker for vascular endothelial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.